Skip to main content
Top
Published in: Journal of Neurology 11/2006

01-11-2006 | ORIGINAL COMMUNICATION

Amyotrophic lateral sclerosis: early predictors of prolonged survival

Authors: Adam Czaplinski, MD, Albert A. Yen, MD, Stanley H. Appel

Published in: Journal of Neurology | Issue 11/2006

Login to get access

Abstract

Objective

In order to define the predictors of prolonged survival available at the time of first examination we performed a historical cohort study of amyotrophis sclerosis (ALS) patients referred to our ALS Clinic over the last 20 years.

Methods

In a group of 1034 patients with the diagnosis of definite or probable ALS the effects of individual prognostic factors on tracheostomy-free survival were assessed with the Kaplan-Meier life-table method. The prognostic value of each factor was estimated using univariate and multivariate Cox proportional hazard analyses.

Results

The median survival time was 3.45 years, (95%CI 3.27–3.74). Both the univariate and multivariate Cox models indicated that younger age, limb site of onset, longer diagnostic delay, lower Appel ALS score (AALSS) at first examination, lower AALSS-rate of change between first symptom and first exam (preslope), and higher baseline forced vital capacity (FVC) were associated with longer survival. In addition, four factors: age, diagnostic delay, baseline FVC and AALSS preslope have been identified as independent predictors of survival in our patient population.

Conclusions

The identification of younger age, limb site of onset and longer diagnostic delay as predictors of prolonged survival in ALS clinic population supports the findings of several, earlier studies that were based on smaller groups of patients. More significantly, several additional variables assessed at the first examination predict longer survival: lower baseline AALSS, lower AALSS- preslope and higher baseline FVC. All of these parameters are of value in patient management and in clinical trial development.
Literature
1.
go back to reference Appel V, Stewart SS, Smith G, Appel SH (1987) A rating scale for amyotrophic lateral sclerosis: Description and preliminary experience. Ann Neurol 22:328–333CrossRefPubMed Appel V, Stewart SS, Smith G, Appel SH (1987) A rating scale for amyotrophic lateral sclerosis: Description and preliminary experience. Ann Neurol 22:328–333CrossRefPubMed
2.
go back to reference Armon C, Graves MC, Moses D, Forte DK, Sepulveda L, Darby SM, Smith RA (2000) Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis. Muscle Nerve 23:874–882CrossRefPubMed Armon C, Graves MC, Moses D, Forte DK, Sepulveda L, Darby SM, Smith RA (2000) Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis. Muscle Nerve 23:874–882CrossRefPubMed
3.
go back to reference Bensimon G, Lacomblez L, Meininger V (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 330:585–591CrossRefPubMed Bensimon G, Lacomblez L, Meininger V (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 330:585–591CrossRefPubMed
4.
go back to reference Brinkmann JR, Andres P, Mendoza M, Sanjak M (1997) Guidelines for the use and performance of quantitative outcome measures in ALS clinical trials. J Neurol Sci 147:97–111CrossRefPubMed Brinkmann JR, Andres P, Mendoza M, Sanjak M (1997) Guidelines for the use and performance of quantitative outcome measures in ALS clinical trials. J Neurol Sci 147:97–111CrossRefPubMed
5.
go back to reference Brooks BR (1994) El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 124:96–107CrossRefPubMed Brooks BR (1994) El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 124:96–107CrossRefPubMed
6.
go back to reference Caroscio JT, Mulvihill MN, Sterling R, Abrams B (1987) Amyotrophic lateral sclerosis: its natural history. Neurol Clin 5:1–8PubMed Caroscio JT, Mulvihill MN, Sterling R, Abrams B (1987) Amyotrophic lateral sclerosis: its natural history. Neurol Clin 5:1–8PubMed
7.
go back to reference Cedarbaum JM, Stambler N (2001) Disease status and use of ventilatory support by ALS patients BDNF Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2:19–22CrossRefPubMed Cedarbaum JM, Stambler N (2001) Disease status and use of ventilatory support by ALS patients BDNF Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2:19–22CrossRefPubMed
8.
go back to reference Chancellor AM, Slattery JM, Fraser H, Swingler RJ, Holloway SM, Warlow CP (1993) The prognosis of adult-onset motor neuron disease: a prospective study based on the Scottish Motor Neuron Disease Register. J Neurol 240:339–346CrossRefPubMed Chancellor AM, Slattery JM, Fraser H, Swingler RJ, Holloway SM, Warlow CP (1993) The prognosis of adult-onset motor neuron disease: a prospective study based on the Scottish Motor Neuron Disease Register. J Neurol 240:339–346CrossRefPubMed
9.
go back to reference Chio A, Mora G, Leone M, Mazzini L, Cocito D, Giordana MT, Bottacchi E, Mutani R (2002) Piemonte and Valle d’Aosta Register for ALS (PARALS) Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology 59:99–103 PubMed Chio A, Mora G, Leone M, Mazzini L, Cocito D, Giordana MT, Bottacchi E, Mutani R (2002) Piemonte and Valle d’Aosta Register for ALS (PARALS) Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology 59:99–103 PubMed
10.
go back to reference Christensen PB, Hojer-Pedersen E, Jensen NB (1990) Survival of patients with amyotrophic lateral sclerosis. Neurology 40:600–604PubMed Christensen PB, Hojer-Pedersen E, Jensen NB (1990) Survival of patients with amyotrophic lateral sclerosis. Neurology 40:600–604PubMed
11.
go back to reference Cox DR (1972) Regression models and life tables. J R Stat Soc B 34:187–220 Cox DR (1972) Regression models and life tables. J R Stat Soc B 34:187–220
12.
go back to reference Cudkowicz ME, Shefner JM, Schoenfeld DA, Brown RH Jr, Johnson H, Qureshi M, Jacobs M, Rothstein JD, Appel SH, Pascuzzi RM, Heiman-Patterson TD, Donofrio PD, David WS, Russell JA, Tandan R, Pioro EP, Felice KJ, Rosenfeld J, Mandler RN, Sachs GM, Bradley WG, Raynor EM, Baquis GD, Belsh JM, Novella S, Goldstein J, Hulihan J (2003) Northeast ALS Consortium A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 61:456–464PubMed Cudkowicz ME, Shefner JM, Schoenfeld DA, Brown RH Jr, Johnson H, Qureshi M, Jacobs M, Rothstein JD, Appel SH, Pascuzzi RM, Heiman-Patterson TD, Donofrio PD, David WS, Russell JA, Tandan R, Pioro EP, Felice KJ, Rosenfeld J, Mandler RN, Sachs GM, Bradley WG, Raynor EM, Baquis GD, Belsh JM, Novella S, Goldstein J, Hulihan J (2003) Northeast ALS Consortium A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 61:456–464PubMed
13.
go back to reference del Aguila MA, Longstreth WT Jr, McGuire V, Koepsell TD, van Belle G (2003) Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 60:813–819 PubMed del Aguila MA, Longstreth WT Jr, McGuire V, Koepsell TD, van Belle G (2003) Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 60:813–819 PubMed
14.
go back to reference Eisen A, Schulzer M, MacNeil M, Pant B, Mak E (1993) Duration of amyotrophic lateral sclerosis is age dependent. Muscle Nerve 116:27–32CrossRef Eisen A, Schulzer M, MacNeil M, Pant B, Mak E (1993) Duration of amyotrophic lateral sclerosis is age dependent. Muscle Nerve 116:27–32CrossRef
15.
go back to reference Haverkamp LJ, Appel V, Appel SH (1995) Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 118:707–719PubMed Haverkamp LJ, Appel V, Appel SH (1995) Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 118:707–719PubMed
16.
go back to reference Jablecki C, Berry C, Leach J (1989) Survival prediction in amyotrophic lateral sclerosis. Muscle Nerve 12:833–841CrossRefPubMed Jablecki C, Berry C, Leach J (1989) Survival prediction in amyotrophic lateral sclerosis. Muscle Nerve 12:833–841CrossRefPubMed
17.
go back to reference Juergens SM, Kurland LT, Okazaki H, Mulder DW (1980) ALS in Rochester, Minnesota, 1925–1977. Neurology 30:463–470PubMed Juergens SM, Kurland LT, Okazaki H, Mulder DW (1980) ALS in Rochester, Minnesota, 1925–1977. Neurology 30:463–470PubMed
18.
go back to reference Kasarskis EJ, Scarlata D, Hill R, Fuller C, Stambler N, Cedarbaum JM (1999) A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials. J Neurol Sci 169:118–125CrossRefPubMed Kasarskis EJ, Scarlata D, Hill R, Fuller C, Stambler N, Cedarbaum JM (1999) A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials. J Neurol Sci 169:118–125CrossRefPubMed
19.
go back to reference Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH, Rowland LP, Levin B, Mitsumoto H (2005) The ALSFRSr predicts survival time in an ALS clinic population. Neurology 64:38–43CrossRefPubMed Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH, Rowland LP, Levin B, Mitsumoto H (2005) The ALSFRSr predicts survival time in an ALS clinic population. Neurology 64:38–43CrossRefPubMed
20.
go back to reference Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347:1425–1431PubMed Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347:1425–1431PubMed
21.
go back to reference Lange DJ, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, Lai EC, Murphy MF, Natter HM, Norris FH, Rudnicki S (1996) Recombinant human insulin-like growth factor-I in ALS: description of a double-blind, placebo-controlled study. North American ALS/IGF-I Study Group. Neurology 47(Suppl 2):S93–94PubMed Lange DJ, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, Lai EC, Murphy MF, Natter HM, Norris FH, Rudnicki S (1996) Recombinant human insulin-like growth factor-I in ALS: description of a double-blind, placebo-controlled study. North American ALS/IGF-I Study Group. Neurology 47(Suppl 2):S93–94PubMed
22.
go back to reference Lange DJ, Murphy PL, Diamond B, Appel V, Lai EC, Younger DS, Appel SH (1998) Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch Neurol 55:93–96CrossRefPubMed Lange DJ, Murphy PL, Diamond B, Appel V, Lai EC, Younger DS, Appel SH (1998) Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch Neurol 55:93–96CrossRefPubMed
23.
go back to reference Lee JR, Annegers JF, Appel SH (1995) Prognosis of amyotrophic lateral sclerosis and the effect of referral selection. J Neurol Sci 132:207–215CrossRefPubMed Lee JR, Annegers JF, Appel SH (1995) Prognosis of amyotrophic lateral sclerosis and the effect of referral selection. J Neurol Sci 132:207–215CrossRefPubMed
24.
go back to reference Louwerse ES, Visser CE, Bossuyt PM, Weverling GJ (1997) Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors. The Netherlands ALS Consortium. J Neurol Sci 152(Suppl 1):S10–17CrossRefPubMed Louwerse ES, Visser CE, Bossuyt PM, Weverling GJ (1997) Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors. The Netherlands ALS Consortium. J Neurol Sci 152(Suppl 1):S10–17CrossRefPubMed
25.
go back to reference Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV (2002) Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve 25:709–714CrossRefPubMed Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV (2002) Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve 25:709–714CrossRefPubMed
26.
go back to reference Mitsumoto H, Davidson M, Moore D, Gad N, Brandis M, Ringel S, Rosenfeld J, Shefner JM, Strong MJ, Sufit R, Anderson FA (2003) ALS CARE Study Group Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction. Amyotroph Lateral Scler Other Motor Neuron Disord 4:177–185CrossRefPubMed Mitsumoto H, Davidson M, Moore D, Gad N, Brandis M, Ringel S, Rosenfeld J, Shefner JM, Strong MJ, Sufit R, Anderson FA (2003) ALS CARE Study Group Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction. Amyotroph Lateral Scler Other Motor Neuron Disord 4:177–185CrossRefPubMed
27.
go back to reference Moore DH, Miller RG (2003) WALS Study Group ALS CARE Study Group ALSRFS as a measure of disease progression and survival. Amyotroph Lateral Scler Other Motor Neuron Disord 4(Suppl 1):C51 Moore DH, Miller RG (2003) WALS Study Group ALS CARE Study Group ALSRFS as a measure of disease progression and survival. Amyotroph Lateral Scler Other Motor Neuron Disord 4(Suppl 1):C51
28.
go back to reference Norris F, Shepherd R, Denys E, U K, Mukai E, Elias L, Holden D, Norris H (1993) Onset, natural history and outcome in idiopathic motor neuron disease. J Neurol Sci 118:48–55CrossRefPubMed Norris F, Shepherd R, Denys E, U K, Mukai E, Elias L, Holden D, Norris H (1993) Onset, natural history and outcome in idiopathic motor neuron disease. J Neurol Sci 118:48–55CrossRefPubMed
29.
go back to reference Preux PM, Couratier P, Boutros-Toni F, Salle JY, Tabaraud F, Bernet-Bernady P, Vallat JM, Dumas M (1996) Survival prediction in sporadic amyotrophic lateral sclerosis : age and clinical form at onset are independent risk factors. Neuroepidemiology 15:153–160PubMed Preux PM, Couratier P, Boutros-Toni F, Salle JY, Tabaraud F, Bernet-Bernady P, Vallat JM, Dumas M (1996) Survival prediction in sporadic amyotrophic lateral sclerosis : age and clinical form at onset are independent risk factors. Neuroepidemiology 15:153–160PubMed
30.
go back to reference Ringel SP, Murphy JR, Alderson MK, Bryan W, England JD, Miller RG, Petajan JH, Smith SA, Roelofs RI, Ziter F (1993) The natural history of amyotrophic lateral sclerosis. Neurology 43:1316–1322PubMed Ringel SP, Murphy JR, Alderson MK, Bryan W, England JD, Miller RG, Petajan JH, Smith SA, Roelofs RI, Ziter F (1993) The natural history of amyotrophic lateral sclerosis. Neurology 43:1316–1322PubMed
31.
go back to reference Stambler N, Charatan M, Cedarbaum JM (1998) Prognostic indicators of survival in ALS. Neurology 50:66–72PubMed Stambler N, Charatan M, Cedarbaum JM (1998) Prognostic indicators of survival in ALS. Neurology 50:66–72PubMed
32.
go back to reference Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman OM (2000) Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study. Arch Neurol 57:1171–1176CrossRefPubMed Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman OM (2000) Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study. Arch Neurol 57:1171–1176CrossRefPubMed
33.
go back to reference Traynor BJ, Zhang H, Shefner JM, Schoenfeld D, Cudkowicz ME; NEALS Consortium (2004) Functional outcome measures as clinical trial endpoints in ALS. Neurology 63:1933–1935PubMed Traynor BJ, Zhang H, Shefner JM, Schoenfeld D, Cudkowicz ME; NEALS Consortium (2004) Functional outcome measures as clinical trial endpoints in ALS. Neurology 63:1933–1935PubMed
34.
go back to reference Turner MR, Parton MJ, Shaw CE, Leigh PN, Al-Chalabi A (2003) Prolonged survival in motor neuron disease a descriptive study of the King’s database 1990–2002. J Neurol Neurosurg Psychiatry 74:995–997CrossRefPubMed Turner MR, Parton MJ, Shaw CE, Leigh PN, Al-Chalabi A (2003) Prolonged survival in motor neuron disease a descriptive study of the King’s database 1990–2002. J Neurol Neurosurg Psychiatry 74:995–997CrossRefPubMed
35.
go back to reference Tysens OB, Vollset SE, Aarli JA (1991) Epidemiology of amyotrophic lateral sclerosis in Hordaland county, western Norway. Acta Neurol Scand 83:280–285CrossRef Tysens OB, Vollset SE, Aarli JA (1991) Epidemiology of amyotrophic lateral sclerosis in Hordaland county, western Norway. Acta Neurol Scand 83:280–285CrossRef
36.
go back to reference Yen AA, Simpson E, Haverkamp LJ, Appel SH (2004) AALS. ALS and Other Motor Neuron Disorders 5(Suppl1):S1–S5 Yen AA, Simpson E, Haverkamp LJ, Appel SH (2004) AALS. ALS and Other Motor Neuron Disorders 5(Suppl1):S1–S5
Metadata
Title
Amyotrophic lateral sclerosis: early predictors of prolonged survival
Authors
Adam Czaplinski, MD
Albert A. Yen, MD
Stanley H. Appel
Publication date
01-11-2006
Publisher
Steinkopff-Verlag
Published in
Journal of Neurology / Issue 11/2006
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-006-0226-8

Other articles of this Issue 11/2006

Journal of Neurology 11/2006 Go to the issue